Catherine Boutsikakis on The Complexities of Hemophilia
Catherine Boutsikakis, Managing Pharmacist – Patient Pharmacy at Cure 4 The Kids Foundation, shared on LinkedIn:
”Thank you Pharmacy Times for the opportunity to discuss the complexities of hemophilia, new treatments available, and the impact on patients and families.”
Watch the full discussion here.
Hemophilia is classified as mild, moderate, or severe based on clotting factor activity, which determines its clinical presentation.
Severe hemophilia is characterized by spontaneous bleeding, especially into joints and muscles, often resulting in chronic pain, limited mobility, and progressive joint damage.
Moderate hemophilia typically leads to bleeding after minor injuries, whereas mild cases usually bleed only with significant trauma or surgical procedures.
Recognizing this spectrum helps clinicians anticipate complications, individualize treatment strategies, and reduce long-term morbidity while preserving quality of life.”
Stay updated with Hemostasis Today.
-
May 30, 2026, 10:27Sartaj Alam: CBC Analyzer – The Backbone of Modern Hematology Diagnostics
-
May 30, 2026, 10:17Factor X Deficiency – From Mild Bruising to Life Threatening Hemorrhage – ICHCC
-
May 30, 2026, 10:06Johann Morelle: Complement Inhibitors Are Reshaping Modern Nephrology
-
May 30, 2026, 09:49Flora Peyvandi: Exploring a Multidisciplinary Care Model for Hemophilia and Rare Diseases
-
May 30, 2026, 08:59Li-Chia Chen: Advancing Patient Care Through Pharmacist Innovation at KUTRRH
-
May 30, 2026, 08:58Ben Creagh-Brown: How Should HI-PEITHO Influence the Management of Intermediate-Risk Pulmonary Embolism?
-
May 30, 2026, 08:56Reidiel Suárez Borges: Understanding the INR in Anticoagulation Management
-
May 29, 2026, 17:23Rita Schwab: Current Clinical Management of Trauma without the Use of Allogenic Blood Products
-
May 29, 2026, 17:22Brian Schiro: Excited to Provide Guideline Based Care at the Aortic Center